Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress

(2012) Kevin S. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

(2011) F. Saad et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

(2011) Janessa J. Laskin et al.   Journal of Thoracic Oncology

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clusterin confers gmcitabine resistance in pancreatic cancer

(2011) Qingfeng Chen et al.   World Journal of Surgical Oncology

Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD

(2010) A. Zoubeidi et al.   CANCER RESEARCH

Overexpression of Clusterin in Ovarian Cancer is Correlated With Impaired Survival

(2010) Guofen F. Yang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

(2010) Kim N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Induction of Clusterin by AKT--Role in Cytoprotection against Docetaxel in Prostate Tumor Cells

(2010) B. Zhong et al.   MOLECULAR CANCER THERAPEUTICS

Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays

(2010) J. Bi et al.   NEOPLASMA

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemosensitization of gemcitabine-resistant human bladder cancer cell line bothin vitroandin vivousing antisense oligonucleotide targeting the anti-apoptotic gene, clusterin

(2009) Mototsugu Muramaki et al.   BJU INTERNATIONAL

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

(2009) S. Chia et al.   CLINICAL CANCER RESEARCH

Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer

(2009) Li Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis

(2009) H Song et al.   ONCOGENE

Serum Level of Clusterin and Its Density in Men with Prostate Cancer as Novel Biomarkers Reflecting Disease Extension

(2009) Hideaki Miyake et al.   UROLOGY

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

(2008) Richard D. Sowery et al.   BJU INTERNATIONAL

A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

(2008) K. N. Chi et al.   CLINICAL CANCER RESEARCH

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY